A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma
Phase of Trial: Phase II
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Pazopanib (Primary) ; Doxorubicin
- Indications Leiomyosarcoma; Liposarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- Acronyms EPAZ
- 30 Mar 2017 Status changed to completed.
- 05 Apr 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 Feb 2016 Planned End Date changed from 1 Sep 2016 to 1 Jan 2017, as reported by ClinicalTrials.gov.